The irreversibility of binding also allows for immune sensitization to off-target adducts (haptenization), which can lead to long-term harm. As noted in a review by Baillie quoting Barf and Kaptein , "the therapeutic applicability or the success of irreversible binding inhibitors is dependent on whether or not the covalent bond can be confined solely to the protein of interest."